Helene Hartvedt Grytli

Author

Oslo University Hospital ORCID

Also Known As

Anders Bjartell, H. Grytli, H.H. Grytli, Helene Grytli, Helene H Grytli, Helene H. Grytli, Helene Hartvedt Grytli

Publications

741

Citations

H-Index

Concepts

All Affiliations

Oslo University Hospital University of Oslo Haukeland University Hospital Skåne University Hospital Umeå University

About

Helene Hartvedt Grytli is an author at Oslo University Hospital specializing in medicine, pharmacotherapy, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	360
2	Health Sciences	1	1	56
3	Cell Biology	1	1	63
4	Health Policy	1	1	56
5	Pathology	1	1	63

Helene Hartvedt Grytli

Publications

637

Citations

H-Index

Page 1

	Year	Citations
Association Between Use of β-Blockers and Prostate Cancer–Specific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High-Risk or Metastatic Disease Helene Hartvedt Grytli, Morten Wang Fagerland, Sophie D. Fosså, European Urology UrologyOncologyCancer EpidemiologyGenitourinary CancerProstate Cancer Patients	2013	241
Use of β‐blockers is associated with prostate cancer‐specific survival in prostate cancer patients on androgen deprivation therapy Helene Hartvedt Grytli, Morten Wang Fagerland, Sophie D. Fosså, The Prostate	2012	141
PBX3 is a putative biomarker of aggressive prostate cancer Håkon Ramberg, Helene Hartvedt Grytli, Ståle Nygård, International Journal of Cancer Prognostic BiomarkersUrologyGenitourinary CancerAggressive Prostate CancerMedicine	2016	63
Benefit‐Risk Assessment of Off‐Label Drug Use in Children: The Bravo Framework Tjitske M. van der Zanden, Miriam G. Mooij, Nienke J. Vet, Clinical Pharmacology & Therapeutics Substance UseBenefit‐risk AssessmentOff‐label Drug UsePharmacotherapyDrug Assessment	2021	56
Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy Peder R. Braadland, Guro F. Giskeødegård, Elise Sandsmark, British Journal of Cancer	2017	43
The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells Peder R. Braadland, Håkon Ramberg, Helene Hartvedt Grytli, Molecular Cancer Research	2019	30
Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification Ingrid Jenny Guldvik, Verena Zuber, Peder R. Braadland, European Urology Open Science	2020	22
Association of β-Blocker Use at Time of Radical Prostatectomy With Rate of Treatment for Prostate Cancer Recurrence Shivanthe Sivanesan, Kristin Austlid Taskén, Helene Hartvedt Grytli JAMA Network Open	2022	20
Low β2-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism Peder R. Braadland, Helene Hartvedt Grytli, Håkon Ramberg, Oncotarget	2015	11
Role of serum response factor expression in prostate cancer biochemical recurrence Maria Prencipe, Aurélie Fabre, Thomas Brendan Murphy, The Prostate	2018	10

Page 1